|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Provalis (PVLS) Announces Update On Strategic Review
11/16/2005 12:06:38 PM
Deeside, Flintshire, UK -- (MARKET WIRE) -- 11/16/2005 --
Provalis plc
Update on strategic review
Provalis plc (LSE: PRO), the international medical diagnostics and pharmaceuticals group, is today providing an update on its previously announced strategic review. This review was initiated by the interim Chief Executive, Peter Woodford, following his appointment on 10 August 2005.
As part of this review, the Board decided to examine the possibility of selling the pharmaceutical business and to that end advisers have been appointed. To date the Board has received several indicative offers which are currently being progressed.
In the Group's preliminary results released on 19 October, the Board stated that, with regard to the medical diagnostic business, it was still too early to predict future sales of in2itTM, and that more permanent funding would be required in due course to develop the Group.
|
|
|
|
|
|
|
|
|
|
|